AstraZeneca Shares Plunge After Reports of Possible $400bn Merger Talks with Bristol Myers
AstraZeneca shares fell sharply amid reports the company held merger talks with U.S. peer Bristol Myers Squibb that could combine the two firms into a near $400 billion pharmaceutical behemoth. Investors and some portfolio managers voiced scepticism about the strategic merits of such a tie-up for AstraZeneca, while a source familiar with the discus…